Patient-controlled analgesia versus intrathecal opioid for pain after cesarean section

Effect of patient-controlled analgesia versus intrathecal opioid injection on patient satisfaction with pain control after cesarean section

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220411054492N1

Enrollment

Registered

2022-07-25

Start date

2017-03-01

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-cesarean section pain. Other acute postprocedural pain

Interventions

Intervention 1: Intervention group 1: 3 ml spinal anesthesia solution containing 12 mg bupivacaine 0.5% (MYLAN S.A.S, France) and 20 mg pethidine (Exir Pharmaceutical Co., Iran) injected intathecally.

Eligibility

Sex/Gender

Female

Age

18 Years to 46 Years

Inclusion criteria

Inclusion criteria: Pregnancy Elective cesarean section ASA class I and II Age: 18-46 years old

Exclusion criteria

Exclusion criteria: Emergency cesarean section Complications during cesarean section

Design outcomes

Primary

Measure	Time frame
Patient satisfaction with analgesia. Timepoint: After gaining consciousness in the recovery and then at 1, 4, and 24 hours in the ward. Method of measurement: Numerical rating scale (NRS).	—

Secondary

Measure	Time frame
Drug side effects. Timepoint: Up to 24 hours after surgery. Method of measurement: Pruritus, nausea and/or vomiting, and respiratory depression (respiratory rate <10/min).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbbas Moallemy

Bandare-abbas University of Medical Sciences

moallymialn@yahoo.com+98 76 3334 5009

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026